Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 279 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MoD2R5l1d3SxeHnjJGF{e2G7 MYW1NEDPxE1? NF;RdGM1QCCq NFG5SXhFVVOR M122ZmtqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> NF:5UG8yODR7OU[0Ny=>
OVCA 429 NXHvPZlvTnWwY4Tpc44hSXO|YYm= NHT3fm0{ODBibl2= M1PFe|Q5KGh? M3LaV2ROW09? NEXDZoRFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> NYrIU4lIOTB7OUm3OlY>
RPMI8226 NHfUR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInKWnAyODBibl2= NFHnNYs1QCCq M3P1RmROW09? MmrkTWM2OD1|MDDuUS=> M1jIVlEyOzB4NEi5
Dox40 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW4NY9JOTByIH7N NFzXPYw1QCCq M3rsS2ROW09? NWDJZ3A6UUN3ME20NEBvVQ>? M{fWTlEyOzB4NEi5
MR20 NFTTc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D1NFExOCCwTR?= NIOzenE1QCCq NXjqd25wTE2VTx?= NGfxOIpKSzVyPUKwJI5O MmHCNVE{ODZ2OEm=
LR5 NVGyWYxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnK[oYyODBibl2= NGLCRXE1QCCq MmXRSG1UVw>? MU\JR|UxRTJyIH7N NWfBN3o3OTF|ME[0PFk>
U266 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqxNFAhdk1? MYC0PEBp NEDoboxFVVOR MYLJR|UxRTNibl2= M1LGdlEyOzB4NEi5
IM-9 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLmZ2YyODBibl2= NGPK[Vk1QCCq MV3EUXNQ NV3QUpJ5UUN3ME22JI5O NWK1ZWlyOTF|ME[0PFk>
Hs Sultan NIrWe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7GUJMyODBibl2= NYPxd2I4PDhiaB?= MXvEUXNQ M4H5PGlEPTB;MkCgcm0> NFz2bJcyOTNyNkS4PS=>
PAM-LY2 MlPZSpVv[3Srb36gRZN{[Xl? NEThZocyODBibl2= M1W5SVEzKGh? MXrEUXNQ Ml[xTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= NEm1TGUyOTN3MEmxNy=>
PAM 212 M13Vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;sb|J2OTByIH7N NV\ncZd5PzJiaB?= MXjEUXNQ MmPQTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MXuxNVM2ODlzMx?=
PAM-LY2 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNFAhdk1? NHnxZXE4OiCq MoXjSG1UVw>? MmPOTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MWexNVM2ODlzMx?=
B4B8 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnGWIQyODBibl2= M{SzdVczKGh? NUDaWldOTE2VTx?= MYnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NFXhWZoyOTN3MEmxNy=>
B7E3 NIrhcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T1SVExOCCwTR?= MV23NkBp M3HoWGROW09? M{THTmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MYGxNVM2ODlzMx?=
UM-SCC-9 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DbIcyODBibl2= MnjIO|IhcA>? M3;YUWROW09? M4LQZWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NGjteWUyOTN3MEmxNy=>
UM-SCC-11B M1\HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvZNVAxKG6P NXyxdINsPzJiaB?= M{m2fmROW09? NH3ZWlFKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NWmzVYpIOTF|NUC5NVM>
H460 M3rtPGZ2dmO2aX;uJGF{e2G7 MYexNEDPxE1? Mkj0NlQhcA>? MYXEUXNQ MmDITY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>? MoHWNVI1QTJzMUe=
U266 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnFOVAxKG6pL33s MkXsOFghcA>? M1TDVGROW09? NIe3[5BKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3XtVlEzPjNzNkG5
ARH77 NYCwRWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nLe|UxOCCwZz;tcC=> NVm2[WlkPDhiaB?= MVzEUXNQ NITHdWhKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NVra[XZKOTJ4M{G2NVk>
WAD-1 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXkSY9HPTByIH7nM41t MnnMOFghcA>? MWnEUXNQ NY\FTJVlUW6qaXLpeJMh[2WubDDndo94fGh? M3zpNVEzPjNzNkG5
U266/LR7 NVn3cGFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nwS|UxOCCwZz;tcC=> MljJOFghcA>? NYD6O3FoTE2VTx?= Ml\YTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXz4bFZEOTJ4M{G2NVk>
U266/dox4 M3TYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrUeJo1PTByIH7nM41t NGjVXYs1QCCq MUXEUXNQ NXfrU5RVUW6qaXLpeJMh[2WubDDndo94fGh? Mlr4NVI3OzF4MUm=
RPMI8226/LR5 NWnE[2l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe4enc2ODBibnevcYw> NIj5coI1QCCq M4H0WmROW09? NXK1VJFkUW6qaXLpeJMh[2WubDDndo94fGh? MUexNlY{OTZzOR?=
H460 M{POSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxe|ExKM7:TR?= MYO3NkBp NGX5SXJFVVOR NUDn[|BpUUN3ME2xNFAhdk1? NXrCbmg{OTJ4M{G2NlA>
H358 M4f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3UlExKM7:TR?= Moj0O|IhcA>? NF\1c25FVVOR NEDYdVJKSzVyPUewJI5O NH2yRlgyOjZ|MU[yNC=>
H322 NWi5V41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNEDPxE1? NU\4bIhyPzJiaB?= NFXPUmhFVVOR MYrJR|UxRTZ{MDDuUS=> Mon3NVI3OzF4MkC=
H460 NEC2PVlHfW6ldHnvckBCe3OjeR?= M4DTZ|ExOCCwTR?= NXLNbGhKOjRiaB?= M3HLSGROW09? NUHoZXlXUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= NFrYc2cyOjZ|MU[yNC=>
LNCap-Pro5 M3TEdmZ2dmO2aX;uJGF{e2G7 MUexJO69VQ>? M{DEPVQhcA>? MlvzSG1UVw>? NHHt[2NUfGGkaXzpfoV{KHB3Mx?= MYWxOFYyOjV|Mh?=
T29 NXjh[olxSXCxcITvd4l{KEG|c3H5 MYq1NEBvVQ>? NHTwbJM1QCCqIB?= MY\EUXNQ Ml\vTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYX2U2MxOTZ5N{ixO|k>
T29Kt1 M3j1V2Fxd3C2b4Ppd{BCe3OjeR?= NV65S5pjPTBibl2= M{PEVVQ5KGhi NXyzeGxFTE2VTx?= NUT2cG91UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlKyNVY4PzhzN{m=
HCT116 M{LFVWFxd3C2b4Ppd{BCe3OjeR?= NE\hR|k2OCCwTR?= M13GRlQ5KGhi MX;EUXNQ NYjmOVV7UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWDoPGV5OTZ5N{ixO|k>
HKe-3 Mnz2RZBweHSxc3nzJGF{e2G7 NF\XRoE2OCCwTR?= NHTGe4Q1QCCqIB?= NEDieXJFVVOR NVruVXU5UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXGxOlc4QDF5OR?=
NB-1691 NH[x[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfONUDPxE1? NE\WeGo4OiCq MWDJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? M4TDOFE4Pjh7Nki0
CHLA-255 NX7sdG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HMOlEh|ryP MVq3NkBp MlrMTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn NH3ablkyPzZ6OU[4OC=>
SK-N-AS NIPvS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr2[IdSOSEQvF2= NHr4OFU4OiCq NXTEb29oUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> M1fQeFE4Pjh7Nki0
NB-1691 M1;oT2Z2dmO2aX;uJGF{e2G7 M33VflExKG6P NGfqfnUzPCCq MnjDV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> NGT3UlYyPzZ6OU[4OC=>
CHLA-255 NVjicVhLTnWwY4Tpc44hSXO|YYm= NVy4Xm9mOTBibl2= NXHNem5YOjRiaB?= NWXaN4RWVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= Mn;pNVc3QDl4OES=
RPMI 8226 NUfpZ2ZHTnWwY4Tpc44hSXO|YYm= M4[4PFIxKG6P MWq4JIg> M1XuUHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NHu5TG8yQTR|NkC1NC=>
MM.1S NWH0NmZNTnWwY4Tpc44hSXO|YYm= M4\KWFIxKG6P NYH5N3VoQCCq M4S1enNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NVLJNFEyOTl2M{[wOVA>
U266 MYnGeY5kfGmxbjDBd5NigQ>? NHPv[FUzOCCwTR?= NXu0eXRDQCCq Mm\aV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MorLNVk1OzZyNUC=
OPM1 M1jx[mZ2dmO2aX;uJGF{e2G7 M3TMUlIxKG6P NH7oTnM5KGh? MXvTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MkjWNVk1OzZyNUC=
INA6 NFWz[llHfW6ldHnvckBCe3OjeR?= NVX5eJQ2OjBibl2= NIfJT3Q5KGh? MYDTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> Mk\yNVk1OzZyNUC=
OPM2 MUXGeY5kfGmxbjDBd5NigQ>? MkHENlAhdk1? M{TZUFghcA>? Mm\3V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MXqxPVQ{PjB3MB?=
RPMI 8226 M4nVRmZ2dmO2aX;uJGF{e2G7 MnfZNlAhdk1? MXi4JIg> Mm\wTY5lfWOnczDEUmEhe3mwdHjld4l{ NHrGTVIyQTR|NkC1NC=>
BaF/3 NWewTGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXTNVAxKG6P M{nLdVQ5KGh? MofQTWM2OD14LkKgcm0> NIXXOIUzODNyNU[5Ni=>
BaF/3-p210 NGG1WVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT0SHhPOTByIH7N NUjBb2tjPDhiaB?= NXSw[5NjUUN3ME20Mlchdk1? M17aPFIxOzB3Nkmy
TCC-S NI\4SG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j4O|ExOCCwTR?= MonkOFghcA>? NUPmdY9qUUN3ME2yMlghdk1? MlnRNlA{ODV4OUK=
BaF/3 MnXpSpVv[3Srb36gRZN{[Xl? MoOwOkBvVQ>? NIDnVmc1QCCq MnXTTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 MUOyNFMxPTZ7Mh?=
BaF/3-p210 M3nJfWZ2dmO2aX;uJGF{e2G7 NF;CUmw3KG6P NHvWR4Q1QCCq MmPTTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> Ml;MNlA{ODV4OUK=
BaF/3-p210 NViwdXlnTnWwY4Tpc44hSXO|YYm= NXvmb2dKPiCwTR?= MnvmNlQhcA>? MkC4VoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? MmjDNlA{ODV4OUK=
Raji MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXsNUDPxE1? MnTiNlQhcA>? NVi0dZIzWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NEnlcXYzOTF5MEm4PC=>
LCL-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxJO69VQ>? NHLNNJczPCCq NFfLZW1T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NGTBPZgzOTF5MEm4PC=>
LCL-2 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPDOZUyKM7:TR?= NFXNSW8zPCCq NGXqWFRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NH3jSFAzOTF5MEm4PC=>
BJAB MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC2cHRwOSEQvF2= NVPTdZhxOjRiaB?= M4T2XnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXGyNVE4ODl6OB?=
SNT-13 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HLU|Eh|ryP MYqyOEBp M3XW[HJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NXfrTXlHOjFzN{C5PFg>
SNT-16 M{DaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\TUYdPOSEQvF2= NH7zNIYzPCCq NUe4NWY5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MlPCNlEyPzB7OEi=
Jurkat NU\OZnR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvRRph4OSEQvF2= NHjVd4gzPCCq NGXMcpNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MVmyNVE4ODl6OB?=
KAI-3 NYHCZ2d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH4bmVDOSEQvF2= M4fkZ|I1KGh? NG\UTmxT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NF7NNFEzOTF5MEm4PC=>
SNK-6 NH;0SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkToNUDPxE1? MUmyOEBp M3:2[nJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MnnwNlEyPzB7OEi=
KHYG-1 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\QNUDPxE1? Ml\2NlQhcA>? M1zkc3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= Ml\SNlEyPzB7OEi=
SNT-16 NHHqblRCeG:ydH;zbZMhSXO|YYm= NXe2WYFvOSEQvF2= NX3lc4pHPiCq MomwTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFnaRlAzOTF5MEm4PC=>
Jurkat M4jDUGFxd3C2b4Ppd{BCe3OjeR?= Mlz0NUDPxE1? NIf3NoE3KGh? M4\mVWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXSyNVE4ODl6OB?=
KAI-3 M3HjdmFxd3C2b4Ppd{BCe3OjeR?= M1jhUlEh|ryP NEPZSHk3KGh? NIrKSFhKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYOyNVE4ODl6OB?=
KHYG-1 M4PhW2Fxd3C2b4Ppd{BCe3OjeR?= M1jxPVEh|ryP MlLOOkBp NV;FSHFDUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mn7ONlEyPzB7OEi=
SNT-13 MmnYRY51cX[rcnHsJGF{e2G7 Ml35NUDPxE1? MXKyOEBp MXXJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NEWxeZgzOTF5MEm4PC=>
SNT-16 NFTLUHBCdnSrdnnyZYwhSXO|YYm= M1rwblEh|ryP MWmyOEBp NH3OdlBKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MUKyNVE4ODl6OB?=
KAI-3 MkjCRY51cX[rcnHsJGF{e2G7 MXexJO69VQ>? NGm0dYozPCCq M{H4Umlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NX70UHN7OjFzN{C5PFg>
SNK-6 MX\BcpRqfmm{YXygRZN{[Xl? NF3iR3kyKM7:TR?= NYHtbm1HOjRiaB?= MoWzTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NYXxNpNpOjFzN{C5PFg>
RAW 264.7 NVi2Z2llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNFAhdk1? NFT6UZU1QCCq MUHS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NYT0VFE1OjJ2MkexOVQ>
A375 M{D1OmFxd3C2b4Ppd{BCe3OjeR?= NIqwNoQyOCCwTR?= MlLhNlQhcA>? M4XyO2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1n1WlI{ODd7MEiz
BLM NV3hZ|RLSXCxcITvd4l{KEG|c3H5 NYfLZVFiOTBibl2= NFPzTWMzPCCq M2jjV2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MV:yN|A4QTB6Mx?=
A375 NVTRSlI2SXW2b4DoZYd6KEG|c3H5 NEDYWmEyOCCwTR?= NYHqbGlUOTJiaB?= MXrJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= Ml\FNlMxPzlyOEO=
BLM NYnVelVmSXW2b4DoZYd6KEG|c3H5 NYjaXJRrOTBibl2= M{m0cFEzKGh? MnnoTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NHvNZWUzOzB5OUC4Ny=>
H1299 NVv5Um5ZSXCxcITvd4l{KEG|c3H5 NWrGUXNyQDBibl2= MkPqNlQhcA>? M2TudmROW09? NYHsVZk4W2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= NGjyNnkzPTN{M{[5Ny=>
Hut-78 NUHY[nVDTnWwY4Tpc44hSXO|YYm= NHX5dmEyODBibl2= MkDUNlQhcA>? NVrKTndiTE2VTx?= M37zfmRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= NEfTXpczPTZ6MUOzOS=>
H9 M4ja[2Z2dmO2aX;uJGF{e2G7 M{PJeFExOCCwTR?= MXiyOEBp NFzXWI5FVVOR M1H0emRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= MViyOVY5OTN|NR?=
HH MXnGeY5kfGmxbjDBd5NigQ>? M4qzelExOCCwTR?= Mki4NlQhcA>? MoLESG1UVw>? MV\kc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? MUiyOVY5OTN|NR?=
Hut-78 MmG5UYloemG2aX;uJGF{e2G7 NH\6fZgyODBibl2= M3i5PFI1KGh? Mln2SG1UVw>? Mnq2VoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= MV6yOVY5OTN|NR?=
HH NGqyXpBOcWe{YYTpc44hSXO|YYm= NH7qT5oyODBibl2= MXeyOEBp NU\CSnlWTE2VTx?= M3zx[HJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW= NHPQbFczPTZ6MUOzOS=>
U937 NYjqU5ZSTnWwY4Tpc44hSXO|YYm= NXKxXm96OTByIH7N MV62JIg> NX[1ZplmUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?= M{jNN|I2PzlzNEe3
human PBMC MWPGeY5kfGmxbjDBd5NigQ>? NWD1VYJ3OTByIH7N MV[yOEBp MlXXTY5lfWOnczDJUE05KHKnbHXhd4U> NF;nS3kzPTd7MUS3Oy=>
ES6 NYe5NmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjiNJZKSzVyPUCuNFAzOSCwTR?= MmO3V2FPT0WU
SK-UT-1 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\qTGlEPTB;MD6xOlMhdk1? NXjndoFpW0GQR1XS
SH-4 NV7tVGtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz3TWM2OD1yLkG3N{BvVQ>? NIf2SmxUSU6JRWK=
TE-9 M2e5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nEOmlEPTB;MD6xPFIhdk1? MVPTRW5ITVJ?
A253 NWDDbHplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rwZWlEPTB;MD6yNFghdk1? NX34UmlQW0GQR1XS
no-10 NX7Lb|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKzbFdKSzVyPUCuNlEhdk1? MmnNV2FPT0WU
MMAC-SF NXTtSHhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK5WGV6UUN3ME2wMlIyPiCwTR?= NGjuT4FUSU6JRWK=
A101D NYHZOFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4VY5wUUN3ME2wMlIzPSCwTR?= NV[0SXAxW0GQR1XS
NTERA-S-cl-D1 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP3TWM2OD1yLkK0N{BvVQ>? M4qz[HNCVkeHUh?=
8-MG-BA M3Tm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMkWgcm0> NGj1NGVUSU6JRWK=
KNS-42 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LQO2lEPTB;MD6yOVghdk1? NHTBNZRUSU6JRWK=
LXF-289 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHVW5dKSzVyPUCuNlY6KG6P NHL3ZoRUSU6JRWK=
OVCAR-4 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfqVnlKSzVyPUCuNlg6KG6P Mo\tV2FPT0WU
LOUCY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLheVhzUUN3ME2wMlI6OyCwTR?= NVPGd4RHW0GQR1XS
BB65-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX75S2V7UUN3ME2wMlMxPCCwTR?= NIjybYxUSU6JRWK=
D-542MG NVXXTW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[xSpoxUUN3ME2wMlMzQSCwTR?= MWLTRW5ITVJ?
ONS-76 NEf2OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zabWlEPTB;MD6zN{BvVQ>? MXHTRW5ITVJ?
BB30-HNC M1\ZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO5e3J7UUN3ME2wMlM{PSCwTR?= M1fSZ3NCVkeHUh?=
KS-1 NX;nWplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwM{Sgcm0> NWX2PYVpW0GQR1XS
A388 M4fJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjyTWM2OD1yLkO1OkBvVQ>? NWnHTmY5W0GQR1XS
ES8 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrsSoxKSzVyPUCuOEBvVQ>? MmTRV2FPT0WU
MZ2-MEL M3nFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofKTWM2OD1yLkSwO{BvVQ>? MUXTRW5ITVJ?
HCC2998 NE\IcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK5fVVKSzVyPUCuOFEzKG6P NUXXO|FRW0GQR1XS
D-247MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwNEGzJI5O MXHTRW5ITVJ?
ACN Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTIN|dZUUN3ME2wMlQyPyCwTR?= MXjTRW5ITVJ?
LB2518-MEL MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPVTWM2OD1yLkSyOUBvVQ>? Ml35V2FPT0WU
ES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNEOgcm0> M3TSUnNCVkeHUh?=
HCE-T NWfNWWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwNEO5JI5O M13TZ3NCVkeHUh?=
OS-RC-2 M1zSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDKTWM2OD1yLkS0JI5O NU\O[5gyW0GQR1XS
MFH-ino MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLnTWM2OD1yLkS0N{BvVQ>? MlrIV2FPT0WU
OCUB-M NXfoVJh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWwTWM2OD1yLkS0O{BvVQ>? M4jTSnNCVkeHUh?=
CP66-MEL M4C3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNEezJI5O NHn2blhUSU6JRWK=
LB771-HNC NFLxfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK2XXg4UUN3ME2wMlQ4PCCwTR?= MYnTRW5ITVJ?
DSH1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO4bmg3UUN3ME2wMlQ5KG6P M3vOT3NCVkeHUh?=
HUTU-80 NXuxTWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwNUOzJI5O MmPFV2FPT0WU
CESS NF7HTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3izdGlEPTB;MD61N|ghdk1? Mm[yV2FPT0WU
NCI-H747 M3TQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwNUO5JI5O NUnH[oV6W0GQR1XS
HT-144 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknBTWM2OD1yLkW3OkBvVQ>? M2DoWnNCVkeHUh?=
COLO-829 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNkG0JI5O MWLTRW5ITVJ?
A4-Fuk MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PoZWlEPTB;MD62NlMhdk1? NYPSfIw1W0GQR1XS
GI-ME-N M1THOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj3WnhKSzVyPUCuOlM1KG6P M4nSdHNCVkeHUh?=
LB831-BLC M3rlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HqT2lEPTB;MD62OFEhdk1? NX7QOIhpW0GQR1XS
HOP-62 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNkS3JI5O MoXuV2FPT0WU
BB49-HNC MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNkWyJI5O MUXTRW5ITVJ?
D-336MG MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHOcodIUUN3ME2wMlY2PyCwTR?= M2TLTXNCVkeHUh?=
TK10 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwNke5JI5O Mmj4V2FPT0WU
Ramos-2G6-4C10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv1RlhyUUN3ME2wMlY6OyCwTR?= NV;Pd3JHW0GQR1XS
LB373-MEL-D M13I[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrnfIRKSzVyPUCuO{BvVQ>? M175PXNCVkeHUh?=
SF126 NILtNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnJZlFKSzVyPUCuO|AyKG6P NIeySmdUSU6JRWK=
UACC-257 NHTpdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwN{Ggcm0> MW\TRW5ITVJ?
KINGS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITVTpZKSzVyPUCuO|IzKG6P MU\TRW5ITVJ?
LS-513 M3;Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfONYVIUUN3ME2wMlc{QSCwTR?= NHmyO4NUSU6JRWK=
GI-1 NHq5d3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PwTGlEPTB;MD63OlQhdk1? MW\TRW5ITVJ?
ES7 NYHBNpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jwdGlEPTB;MD63OlYhdk1? M3XBTXNCVkeHUh?=
LB2241-RCC Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHvTWM2OD1yLkiwOEBvVQ>? NVzRN4ZxW0GQR1XS
D-263MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f6cmlEPTB;MD64NFchdk1? Mlm0V2FPT0WU
SW684 NIDOSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXJTW1iUUN3ME2wMlgzOSCwTR?= MkGzV2FPT0WU
ML-2 NFvMTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwOEKxJI5O MlWyV2FPT0WU
SK-LMS-1 MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn0cYI3UUN3ME2wMlg2PCCwTR?= NFHYWYVUSU6JRWK=
TE-5 NWPqTGlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjZdlZKSzVyPUCuPFY2KG6P NWHhbFl4W0GQR1XS
QIMR-WIL NYrFeY53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TOO2lEPTB;MD64PFkhdk1? NY\lTZBxW0GQR1XS
NCI-H1355 NHXuW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwOEm1JI5O MWTTRW5ITVJ?
SNB75 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TDfWlEPTB;MD65NVIhdk1? M4jyc3NCVkeHUh?=
RXF393 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XtTGlEPTB;MD65NVQhdk1? MmnJV2FPT0WU
IST-MEL1 M1v6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTlTWM2OD1yLkmxO{BvVQ>? MnTFV2FPT0WU
SF268 M3\TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[0VGNKSzVyPUCuPVI{KG6P MlnvV2FPT0WU
KALS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn3fGdKSzVyPUCuPVI2KG6P MWfTRW5ITVJ?
HC-1 NEfGeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXixWVl4UUN3ME2wMlk4PSCwTR?= NEKyWoxUSU6JRWK=
SW872 M1Tmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrs[FlIUUN3ME2wMlk6PiCwTR?= NGLESHdUSU6JRWK=
PSN1 NIHUbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofMTWM2OD1zLkCxJI5O MU\TRW5ITVJ?
TE-1 M3HtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMEOgcm0> M{K1dnNCVkeHUh?=
TE-10 NYLLXJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nqPGlEPTB;MT6wN{BvVQ>? M1j2[3NCVkeHUh?=
RKO NG\SPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;jPGlEPTB;MT6wOkBvVQ>? M{HlfHNCVkeHUh?=
LC-2-ad NYC3[XE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;QW|BKSzVyPUGuNFghdk1? MWfTRW5ITVJ?
SK-MM-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwMEmgcm0> MoC2V2FPT0WU
VA-ES-BJ M3Ltfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TabmlEPTB;MT6wPUBvVQ>? NX\aSplVW0GQR1XS
MZ7-mel NWS2bpljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W5fmlEPTB;MT6wPUBvVQ>? NGGx[ItUSU6JRWK=
D-392MG MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPhTWM2OD1zLkGgcm0> NUfmZYk1W0GQR1XS
CCRF-CEM NXq1XJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMUOgcm0> NI\x[3dUSU6JRWK=
EM-2 NFPiOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK2TWM2OD1zLkG2JI5O NHjQ[oFUSU6JRWK=
HAL-01 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwMUigcm0> Mom1V2FPT0WU
TE-8 NFXZcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwMUmgcm0> NFeyPXRUSU6JRWK=
NCI-H1882 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\lNZd4UUN3ME2xMlIhdk1? MUjTRW5ITVJ?
Daudi MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT4fpRoUUN3ME2xMlIzKG6P MnPwV2FPT0WU
BL-41 M2OxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPib4VKSzVyPUGuNlUhdk1? M3;V[nNCVkeHUh?=
SR MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrV[YVkUUN3ME2xMlI2KG6P NF;hW3pUSU6JRWK=
KM12 M33xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\peJNKSzVyPUGuNlchdk1? M3XCZXNCVkeHUh?=
K5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm5TWM2OD1zLkK4JI5O MXTTRW5ITVJ?
A3-KAW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojDTWM2OD1zLkK4JI5O MXLTRW5ITVJ?
CMK NX62Z456T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfJTWM2OD1zLkK5JI5O MmfPV2FPT0WU
Calu-6 M1Oy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy4V2pjUUN3ME2xMlI6KG6P NYfkOnc3W0GQR1XS
IST-SL2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K3fWlEPTB;MT6zNUBvVQ>? NX;tZnljW0GQR1XS
OPM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33McWlEPTB;MT6zN{BvVQ>? MnjJV2FPT0WU
DU-4475 M1PMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;VNnhMUUN3ME2xMlM3KG6P MoPPV2FPT0WU
ECC12 MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nLWWlEPTB;MT6zO{BvVQ>? NVPOdZJzW0GQR1XS
L-540 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP4emk5UUN3ME2xMlM4KG6P M1rEcXNCVkeHUh?=
CAS-1 NVnjOG5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TiTmlEPTB;MT6zO{BvVQ>? MkWzV2FPT0WU
PF-382 M{j3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNEegcm0> NGf5PIhUSU6JRWK=
LS-411N MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX6TWM2OD1zLkWzJI5O MkjBV2FPT0WU
NCI-H69 M2rCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwNUSgcm0> NYHSbYZ{W0GQR1XS
NB12 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwNU[gcm0> Ml:1V2FPT0WU
HEL M{O4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0TWM2OD1zLk[xJI5O NI\lXIdUSU6JRWK=
GCIY NWK1TJdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW1dZE2UUN3ME2xMlYzKG6P MoW2V2FPT0WU
EHEB NHvnWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H1TGlEPTB;MT62O{BvVQ>? M4HoenNCVkeHUh?=
TGBC1TKB M3HzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXzToF[UUN3ME2xMlcyKG6P MUHTRW5ITVJ?
KURAMOCHI MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCzTYlTUUN3ME2xMlczKG6P MUHTRW5ITVJ?
U-266 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\je4prUUN3ME2xMlc3KG6P NWLKWmREW0GQR1XS
LC4-1 NXfnNHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TJOGlEPTB;MT63PUBvVQ>? MVjTRW5ITVJ?
NCI-H2126 NW\oW3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi2PYFKSzVyPUGuPEBvVQ>? NVjudJhmW0GQR1XS
NCI-H1092 M{DYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\DPGlEPTB;MT64JI5O NITMR4xUSU6JRWK=
GB-1 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ITWM2OD1zLkixJI5O NH3sco5USU6JRWK=
MV-4-11 NYK4cWZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFwOEKgcm0> NV;vPZhNW0GQR1XS
Becker MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLSTWM2OD1zLkizJI5O MV;TRW5ITVJ?
MPP-89 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW5XXBIUUN3ME2xMlg6KG6P MortV2FPT0WU
BE-13 M37xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrGTWM2OD1zLkmzJI5O MkjNV2FPT0WU
697 NFj4TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwOUmgcm0> MmHQV2FPT0WU
NKM-1 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJibl2= M{LaSHNCVkeHUh?=
NB13 M{PLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG2cJdKSzVyPUKgcm0> Mo[yV2FPT0WU
LS-123 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrNTW9KSzVyPUKuNFIhdk1? NXzPU2xTW0GQR1XS
NB17 NVTrUm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGCzTlhKSzVyPUKuNFQhdk1? M1;jcHNCVkeHUh?=
LAN-6 NXHuNYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G1bGlEPTB;Mj6wOUBvVQ>? NHy4V3ZUSU6JRWK=
EW-24 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PtNGlEPTB;Mj6wPEBvVQ>? M1zyc3NCVkeHUh?=
NOS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwMUGgcm0> MYfTRW5ITVJ?
BL-70 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XFNWlEPTB;Mj6xNkBvVQ>? MYnTRW5ITVJ?
GT3TKB M4G3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zQZ2lEPTB;Mj6xNkBvVQ>? M1XtWnNCVkeHUh?=
HH NITieYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GVpRKSzVyPUKuNVMhdk1? MXvTRW5ITVJ?
KE-37 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3McJV1UUN3ME2yMlE{KG6P NHns[ZNUSU6JRWK=
MOLT-4 NF;uOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLcmlEPTB;Mj6xN{BvVQ>? M2iycnNCVkeHUh?=
EKVX MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJwMUSgcm0> MYjTRW5ITVJ?
KGN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXmb4ltUUN3ME2yMlE2KG6P NFzlSXJUSU6JRWK=
ES4 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:0PWlEPTB;Mj6xOkBvVQ>? NX;5cldPW0GQR1XS
SJSA-1 NF\qZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwMkGgcm0> MonEV2FPT0WU
KMOE-2 NIOxXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\i[ZdKSzVyPUKuNlMhdk1? MnTaV2FPT0WU
NB5 NYfBS2U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q2VWlEPTB;Mj6yO{BvVQ>? M2Di[nNCVkeHUh?=
BC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO5UIJKSzVyPUKuN|Ehdk1? MX7TRW5ITVJ?
NB10 M1LmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZS4RiUUN3ME2yMlMzKG6P M3TQc3NCVkeHUh?=
RPMI-8226 NVfJb4NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwM{Wgcm0> NEPrPGdUSU6JRWK=
SCC-3 M4f3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPYfFRKSzVyPUKuN|chdk1? M2\rNnNCVkeHUh?=
ARH-77 M1fTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTiXlVKSzVyPUKuN|ghdk1? MoXUV2FPT0WU
NCI-H748 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLJSZFKSzVyPUKuN|khdk1? MXvTRW5ITVJ?
KU812 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi3UGVKSzVyPUKuOFIhdk1? MoXBV2FPT0WU
NCI-H64 M2WyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rCVGlEPTB;Mj60OEBvVQ>? M4jJeHNCVkeHUh?=
NB69 NI\4T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfUbGVnUUN3ME2yMlQ3KG6P MXPTRW5ITVJ?
KNS-81-FD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwNEigcm0> NFTiPVhUSU6JRWK=
LB1047-RCC Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TadWlEPTB;Mj61O{BvVQ>? MnXJV2FPT0WU
EB-3 NHLJPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJwNk[gcm0> MYHTRW5ITVJ?
Mo-T MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLsXHpSUUN3ME2yMlc1KG6P NVzQeopuW0GQR1XS
EW-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\4TWM2OD1{Lke1JI5O NYnJU4ZxW0GQR1XS
CTV-1 MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLzTWM2OD1{Lkigcm0> NYq3ToR6W0GQR1XS
ETK-1 M2HJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P1WGlEPTB;Mj64OEBvVQ>? M1\pSnNCVkeHUh?=
C2BBe1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D2TGlEPTB;Mj64PUBvVQ>? MV7TRW5ITVJ?
MOLT-16 M2DS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\KV5ZKSzVyPUKuPFkhdk1? NGTzbIlUSU6JRWK=
SW954 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C1WGlEPTB;Mj65JI5O NH\6d|JUSU6JRWK=
HT Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:4N2dIUUN3ME2zMlAzKG6P NXTRdodXW0GQR1XS
KARPAS-299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4noV2lEPTB;Mz6wOkBvVQ>? NVjYTpBGW0GQR1XS
MONO-MAC-6 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT4WHNKSzVyPUOuNUBvVQ>? NHywWGJUSU6JRWK=
CGTH-W-1 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;lWmxKSzVyPUOuNUBvVQ>? NVH1[|VrW0GQR1XS
SK-PN-DW NULrb2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnWe3Y2UUN3ME2zMlE1KG6P MYjTRW5ITVJ?
CW-2 M{S0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPTTWM2OD1|LkKxJI5O NET2NpdUSU6JRWK=
SK-N-DZ NYS0fYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrzfotNUUN3ME2zMlI3KG6P M1j6RnNCVkeHUh?=
NEC8 NXzLPVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwM{Wgcm0> NW[5VXViW0GQR1XS
LB996-RCC NHv5Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\4SFdKSzVyPUOuOEBvVQ>? NHfwVVZUSU6JRWK=
DB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzrPWlDUUN3ME2zMlQyKG6P M2nQ[HNCVkeHUh?=
TE-15 NVnuNXFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTGTWM2OD1|LkSzJI5O M1WxfnNCVkeHUh?=
COR-L88 NE\4cGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjrcoVKSzVyPUOuOFchdk1? MkH0V2FPT0WU
LAMA-84 NFvLZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L4R2lEPTB;Mz60PUBvVQ>? Mo\1V2FPT0WU
MEG-01 NUjQc|ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX2TWM2OD1|LkS5JI5O MYjTRW5ITVJ?
LOXIMVI NILqVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHGUmVKSzVyPUOuOUBvVQ>? NF;OPIJUSU6JRWK=
RPMI-8402 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;WXlluUUN3ME2zMlUhdk1? M1z0VHNCVkeHUh?=
KARPAS-45 NHjXUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nEemlEPTB;Mz61OEBvVQ>? MVPTRW5ITVJ?
HCC1187 NIS0VZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ftXGlEPTB;Mz61OEBvVQ>? NYPUT5RHW0GQR1XS
MZ1-PC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOzTYdTUUN3ME2zMlU1KG6P M2nJ[HNCVkeHUh?=
no-11 M{jPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTBTWM2OD1|LkW1JI5O MlrxV2FPT0WU
EVSA-T MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ndIpKSzVyPUOuOkBvVQ>? MknjV2FPT0WU
DJM-1 NULrTXRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnwSGZKSzVyPUOuOlMhdk1? MVfTRW5ITVJ?
COLO-684 NIDrTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwNk[gcm0> NFvjVIpUSU6JRWK=
NMC-G1 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;KR5JKSzVyPUOuOlghdk1? M4r3S3NCVkeHUh?=
LC-1F NYfKV25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PQbWlEPTB;Mz63OEBvVQ>? M2TYe3NCVkeHUh?=
RL95-2 NUHQdJJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne3TWM2OD1|Lke5JI5O M2rJ[XNCVkeHUh?=
COLO-320-HSR MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCbm9KSzVyPUOuPVIhdk1? M3PQfnNCVkeHUh?=
RCC10RGB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W4U2lEPTB;Mz65N{BvVQ>? Mmn3V2FPT0WU
HD-MY-Z MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwOUOgcm0> MlPHV2FPT0WU
NCI-H2141 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPkO2NGUUN3ME20MlA2KG6P NWrTenp5W0GQR1XS
K-562 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHSUXpKSzVyPUSuNVIhdk1? MmnnV2FPT0WU
NCI-H1648 M1G0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;FbYw1UUN3ME20MlE{KG6P NHG0OpBUSU6JRWK=
OMC-1 M2jVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETid5pKSzVyPUSuNVghdk1? MWPTRW5ITVJ?
LB647-SCLC NXLaVoFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq0SpRqUUN3ME20MlIzKG6P Mn\HV2FPT0WU
TE-12 NFj4NGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRwMkWgcm0> NVu5PXhzW0GQR1XS
NOMO-1 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f5VGlEPTB;ND6zN{BvVQ>? NXnlPHRDW0GQR1XS
Raji NFfhPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfwWoxDUUN3ME20MlQ3KG6P NGCxfI1USU6JRWK=
NALM-6 M3ftVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S3XWlEPTB;ND60PUBvVQ>? Moe4V2FPT0WU
HL-60 NHnuWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfnOVBuUUN3ME20MlY4KG6P MVTTRW5ITVJ?
IST-SL1 NX3OO2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzOT2pKSzVyPUSuOlghdk1? M2W0[HNCVkeHUh?=
MHH-PREB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwOE[gcm0> MWHTRW5ITVJ?
MHH-NB-11 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXrTWRDUUN3ME20MlkyKG6P MonkV2FPT0WU
JiyoyeP-2003 MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW5XGhKSzVyPUWgcm0> M1\Q[XNCVkeHUh?=
SBC-1 NWjDNXJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jMUWlEPTB;NT6wNUBvVQ>? NFvzRoxUSU6JRWK=
CHP-126 NFfPbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULnXo5tUUN3ME21MlA3KG6P NVPvVFhqW0GQR1XS
LU-139 NHPONVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrvTWM2OD13LkGzJI5O NYrybmZbW0GQR1XS
NCI-SNU-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrdpdKSzVyPUWuNVchdk1? NXnqRXl4W0GQR1XS
SW962 NUfnOYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\oS|hKSzVyPUWuNlEhdk1? MWHTRW5ITVJ?
EW-1 NETLbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTVwM{Ggcm0> M3\Zc3NCVkeHUh?=
NCI-H1417 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LBN2lEPTB;NT61NUBvVQ>? Ml7xV2FPT0WU
LU-65 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP3TWM2OD13Lki0JI5O MWPTRW5ITVJ?
D-502MG NYHrN3lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnCOVN7UUN3ME22MlM4KG6P M3XvRnNCVkeHUh?=
BC-3 NEH6cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjZdVNKSzVyPU[uOlEhdk1? Mlj4V2FPT0WU
GDM-1 M4GzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ITWM2OD14Lke3JI5O M{\pZnNCVkeHUh?=
NCI-H2196 M2HDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZwODDuUS=> NHXDWFVUSU6JRWK=
NB1 NGHWbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLxcG1PUUN3ME22Mlg5KG6P MYXTRW5ITVJ?
NCI-H345 NGHDeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqxTWM2OD15LkKgcm0> MXzTRW5ITVJ?
SU-DHL-1 NWXZdHdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;3PGlEPTB;Nz6yOEBvVQ>? NX\reYpZW0GQR1XS
JVM-2 NGLodmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzCTWM2OD15LkK4JI5O MoH0V2FPT0WU
LU-134-A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrvdW9KSzVyPUeuN|khdk1? MYXTRW5ITVJ?
NCI-H1694 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSzTWM2OD15LkW4JI5O NIXib3lUSU6JRWK=
NCI-SNU-16 M{LtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\DTWM2OD15Lk[1JI5O MluzV2FPT0WU
L-363 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HyUmlEPTB;Nz63JI5O NGm1UG9USU6JRWK=
KG-1 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTdwOUSgcm0> NEXnXFNUSU6JRWK=
MN-60 NXjUeW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTaTWM2OD16LkG0JI5O MX3TRW5ITVJ?
NB6 NF35VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnVTGVKSzVyPUiuOFghdk1? M4DVcXNCVkeHUh?=
MLMA NIPlRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXKO3pKSzVyPUiuPFUhdk1? MXzTRW5ITVJ?
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jYNGlEPTB;OD64PUBvVQ>? MYHTRW5ITVJ?
SK-NEP-1 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjIXVZoUUN3ME25MlAyKG6P NIHHcIhUSU6JRWK=
DMS-114 NV7i[pJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTlwNkKgcm0> MoHjV2FPT0WU
CTB-1 M3;ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfBc5ZMUUN3ME25MlY4KG6P M4rT[HNCVkeHUh?=
NCI-H2081 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XMVmlEPTB;MUCuNFkhdk1? MoHWV2FPT0WU
ES5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33LTmlEPTB;MUCuN|ghdk1? NXLqW4c3W0GQR1XS
HCC1599 M1Ttb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\3O|FKSzVyPUGxMlkyKG6P NEXyS2pUSU6JRWK=
NCI-H23 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH0c4tIUUN3ME2xNk4yOiCwTR?= NUfrXpg1W0GQR1XS
NCI-H1581 NWrRTFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH2TWM2OD1zMj6yPEBvVQ>? M3i3OnNCVkeHUh?=
JVM-3 NU\EOWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnrW3lwUUN3ME2xNk46QSCwTR?= NW[zem16W0GQR1XS
NCI-SNU-1 M2XYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T1PGlEPTB;MUOuNVkhdk1? NYm0eFNYW0GQR1XS
NB7 NYnFWWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\wPGlEPTB;MUWuPVIhdk1? NIm3O4tUSU6JRWK=
JAR Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7XNGdKSzVyPUG2MlE{KG6P NIGzbWNUSU6JRWK=
TGW M3;PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fudmlEPTB;MU[uOFghdk1? MXXTRW5ITVJ?
U-87-MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HvRWlEPTB;MU[uO|Yhdk1? M{XjcnNCVkeHUh?=
NCI-H1436 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF5LkCxJI5O MVzTRW5ITVJ?
GOTO Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OwSmlEPTB;MUeuNFYhdk1? M3LVbHNCVkeHUh?=
COLO-800 NUDnOZRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF5Lk[0JI5O MV;TRW5ITVJ?
MFM-223 NYSzPJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF5LkmxJI5O MnTZV2FPT0WU
EW-18 M1rucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yzbmlEPTB;MUeuPVYhdk1? M{XrWXNCVkeHUh?=
NB14 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF5Lkm4JI5O MX7TRW5ITVJ?
EB2 NYCzd416T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Lie2lEPTB;MUiuNFghdk1? NY\3SII1W0GQR1XS
EoL-1- NUP6UI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXlVZJCUUN3ME2xPE4{OSCwTR?= MmLYV2FPT0WU
NCCIT MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfxdlBKSzVyPUG4MlM3KG6P M2j1OHNCVkeHUh?=
DG-75 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF6Lk[xJI5O MXfTRW5ITVJ?
HCC2218 M1W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF7LkWgcm0> MkOwV2FPT0WU
TE-6 NYLaZnJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEezR41KSzVyPUKwMlA5KG6P NWftVHE{W0GQR1XS
SF539 M4OxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHGboZNUUN3ME2yNE43PyCwTR?= M3L3fHNCVkeHUh?=
NCI-H446 NYTjW2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvyTWFuUUN3ME2yNU4yQCCwTR?= M1fQU3NCVkeHUh?=
IST-MES1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ{Lke3JI5O Mn75V2FPT0WU
NCI-H82 M2f4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn2TWM2OD1{Mz6wNkBvVQ>? NVHOe2VWW0GQR1XS
HCC2157 NEfLV|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ|LkGzJI5O M2XRPHNCVkeHUh?=
EW-12 MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ|LkG3JI5O MWjTRW5ITVJ?
SIMA MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TscGlEPTB;MkOuN|ghdk1? M1XPWHNCVkeHUh?=
DOHH-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ|LkS1JI5O NV;I[GVQW0GQR1XS
IM-9 M3X3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ|LkW0JI5O NX21XGtYW0GQR1XS
EC-GI-10 M3LsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ2LkKzJI5O Mn:1V2FPT0WU
HDLM-2 NHH5SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu0[IFVUUN3ME2yOE42PCCwTR?= NVr0bpZwW0GQR1XS
LS-1034 NX\KbVFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm2V2Q3UUN3ME2yOU44PSCwTR?= MYDTRW5ITVJ?
REH M2W5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBdGlEPTB;Mk[uOFEhdk1? NGTOfo1USU6JRWK=
LU-165 M1;remdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fjUmlEPTB;Mk[uO|Ihdk1? MojFV2FPT0WU
NH-12 NWC1PWt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PnXGlEPTB;MkeuOlchdk1? NWjK[GtlW0GQR1XS
WSU-NHL Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OzcmlEPTB;MkiuN|khdk1? MlvVV2FPT0WU
ECC4 M{C4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HEdmlEPTB;MkiuO|khdk1? M2X3e3NCVkeHUh?=
OCI-AML2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ7Lk[5JI5O MXXTRW5ITVJ?
EW-3 NH7xdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXHb5VKSzVyPUOwMlU6KG6P MoLLV2FPT0WU
NCI-H526 NX3V[YlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\FS2lEPTB;M{KuOVQhdk1? MorPV2FPT0WU
NCI-H719 M4niUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XWXmlEPTB;M{SuN|Ehdk1? NIP4OoJUSU6JRWK=
KARPAS-422 NUnqUZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WzXmlEPTB;M{WuNFQhdk1? NEPDV2xUSU6JRWK=
SK-MEL-1 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTN3LkG3JI5O M3XzNnNCVkeHUh?=
ES3 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nXV2lEPTB;M{WuNVkhdk1? NEe0XoNUSU6JRWK=
UACC-812 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvSO2xKSzVyPUO1MlQ1KG6P MnziV2FPT0WU
C8166 NIq1V4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN3Lkegcm0> MnH4V2FPT0WU
MDA-MB-134-VI NELLd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e5S2lEPTB;M{WuPFchdk1? MXfTRW5ITVJ?
D-283MED MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvMTWM2OD1|Nz63PUBvVQ>? MUTTRW5ITVJ?
SHP-77 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXeVF1UUN3ME2zPE4xOyCwTR?= MnziV2FPT0WU
NCI-H2227 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1exSWlEPTB;NECuOFkhdk1? MV;TRW5ITVJ?
SKM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnNTXRmUUN3ME20Nk43OyCwTR?= MWPTRW5ITVJ?
L-428 M1TkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37UT2lEPTB;NEOuPFYhdk1? NXjJZ3N{W0GQR1XS
RPMI-6666 NYDrcY9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHYTWM2OD12NT64PUBvVQ>? M3vJfHNCVkeHUh?=
NCI-H716 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3MN3FKSzVyPUS4MlgyKG6P NIjr[m9USU6JRWK=
DMS-79 M1izSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPqR2lKSzVyPUWwMlcyKG6P NUn6NJprW0GQR1XS
RS4-11 NXLqOYNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jaV2lEPTB;NUCuPFghdk1? NILkblZUSU6JRWK=
NCI-H720 M13ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxPHNKSzVyPUWxMlEyKG6P MULTRW5ITVJ?
MC-CAR M{fjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\aNFlKSzVyPUWxMlUzKG6P MofZV2FPT0WU
TALL-1 M4[yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPBTWM2OD13Mz65NUBvVQ>? NHfQWW9USU6JRWK=
NCI-N87 NGfQeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSzTWM2OD13ND6xPEBvVQ>? NVr0Wm9qW0GQR1XS
P30-OHK MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTV2Lk[xJI5O MUPTRW5ITVJ?
LP-1 M2HK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITCfohKSzVyPU[xMlI5KG6P M1;OZnNCVkeHUh?=
YT NUnGepN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SybGlEPTB;NkGuPEBvVQ>? MnzNV2FPT0WU
MRK-nu-1 M13DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXKfZk4UUN3ME22NU45OiCwTR?= M{CwSXNCVkeHUh?=
BT-474 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZ3IH7N M3Pq[3NCVkeHUh?=
NCI-H322M M3fYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZ4LkGxJI5O M{\BXnNCVkeHUh?=
NCI-H128 M4ixZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KwfWlEPTB;N{SuO|chdk1? M3WyT3NCVkeHUh?=
KMS-12-PE NYDvfJFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTd4LkK0JI5O NH\pOXdUSU6JRWK=
KP-N-YS MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDrdopKSzVyPUe2Mlc1KG6P NXL3SVVkW0GQR1XS
ALL-PO M323SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknVTWM2OD15Nz62OkBvVQ>? MWDTRW5ITVJ?
EW-13 M1PPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\PNXZKSzVyPUe3Mlc3KG6P MlXrV2FPT0WU
EW-11 NIDiPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKySVNKSzVyPUe4MlUzKG6P NFLKV3RUSU6JRWK=
SK-N-FI NGjvOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfHdoV7UUN3ME24NE4zKG6P M32zTnNCVkeHUh?=
CAL-148 M4nNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;yTWM2OD16MT64OEBvVQ>? NXnvSolPW0GQR1XS
RL NGP5c4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm4TWM2OD16Nj6wPUBvVQ>? NF3teZFUSU6JRWK=
AM-38 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLtSGxsUUN3ME24PE4xQCCwTR?= MVrTRW5ITVJ?
RH-1 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrobI4xUUN3ME25PU45PSCwTR?= M4f5fnNCVkeHUh?=
NCI-H1770 M4DyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3hTWM2OD1zMEKuOFkhdk1? Mm\DV2FPT0WU
SIG-M5 NGjDTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnWcmJNUUN3ME2xNFUvODZibl2= NXzzN|NSW0GQR1XS
GR-ST NYiwOWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6xcJc{UUN3ME2xNVMvOzRibl2= MYnTRW5ITVJ?
ST486 NHmwd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2cWlEPTB;MUG0MlA3KG6P NIrje2pUSU6JRWK=
NCI-H1650 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDLXFhKSzVyPUGxOU4zQSCwTR?= M4m5THNCVkeHUh?=
MHH-CALL-2 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3pT2V1UUN3ME2xNVUvPyCwTR?= MWfTRW5ITVJ?
BV-173 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF{Mj63NUBvVQ>? NFTaUWpUSU6JRWK=
MC116 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF2OD64OUBvVQ>? Mof0V2FPT0WU
NCI-H524 M3zpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiwTWM2OD1zNUmuNUBvVQ>? NYXQV3JxW0GQR1XS
SCLC-21H NYP5VYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF3OT60NUBvVQ>? MmfJV2FPT0WU
NCI-H1304 M{m2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGzTWM2OD1zNkmuNlEhdk1? NIHLN2ZUSU6JRWK=
NCI-H510A NG\SRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF6NT6zO{BvVQ>? M1\mN3NCVkeHUh?=
NCI-H209 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\kTWM2OD1zOU[uOVIhdk1? MYjTRW5ITVJ?
KM-H2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF7Nz6wOUBvVQ>? M{jiVXNCVkeHUh?=
NCI-H1395 M{\mU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\FcGFjUUN3ME2yNVAvOTNibl2= NWjmeHJvW0GQR1XS
NCI-H1155 M3L0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jIeWlEPTB;MkOwMlMzKG6P MUPTRW5ITVJ?
COR-L279 NV;lN3hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvQVnRKSzVyPUK1Nk4yPyCwTR?= NEfsOHVUSU6JRWK=
NCI-H1299 NWrWd4pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrQTWM2OD1{NkGuO|Ehdk1? M2fzV3NCVkeHUh?=
EW-22 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nncmlEPTB;Mk[zMlc2KG6P MUTTRW5ITVJ?
SK-MEL-2 M1PHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLsVlRKSzVyPUK4NU46KG6P NYficFcyW0GQR1XS
KASUMI-1 NXTaWmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ6Mz6wOUBvVQ>? M{e4RXNCVkeHUh?=
NCI-H187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ6Nz6wPEBvVQ>? NVn1SWFzW0GQR1XS
NCI-H2171 NYfQNIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPwTWM2OD1{OEiuPVIhdk1? MVLTRW5ITVJ?
LNCaP-Clone-FGC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILibVhKSzVyPUK5OU4zPiCwTR?= NU\vWoN{W0GQR1XS
NCI-H1522 NI\0[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTNyNz6wOUBvVQ>? MlHSV2FPT0WU
SCH Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzIO5VXUUN3ME2zNlIvOjJibl2= MmnZV2FPT0WU
THP-1 NYL0OJJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3Uc5BKSzVyPUOyNk43KG6P MX;TRW5ITVJ?
SNU-C1 NHXpN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTzdJVKSzVyPUO2Nk4xQSCwTR?= Ml:5V2FPT0WU
CA46 NUPMTIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnnNINKSzVyPUO3N{43OyCwTR?= NIjIO4dUSU6JRWK=
NCI-H1963 NYTPclg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN6Nj6xPUBvVQ>? M4rKOXNCVkeHUh?=
DEL NGnaR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITONYNKSzVyPUO5NU4zPyCwTR?= NIrtO3JUSU6JRWK=
TUR NELFZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7rPXZKSzVyPUO5Ok43OSCwTR?= M1\lVHNCVkeHUh?=
NCI-H226 NFr6RlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLHZYZKSzVyPUSwN{4zOyCwTR?= NH[4[2RUSU6JRWK=
COLO-668 M{K1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TJZmlEPTB;NECzMlU4KG6P MljmV2FPT0WU
CPC-N MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXGenNKSzVyPUSwN{44PyCwTR?= MnHZV2FPT0WU
NCI-H889 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfD[4xQUUN3ME20OlEvQTJibl2= NVrG[XRlW0GQR1XS
J-RT3-T3-5 M2nVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP0WG1KSzVyPUWzNk42PyCwTR?= M3:5[nNCVkeHUh?=
MSTO-211H MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDzfGlKSzVyPUW3OE4zPiCwTR?= NE\SXJFUSU6JRWK=
SCC-15 NHy2PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPVXY1ZUUN3ME22OlcvPDdibl2= MoDCV2FPT0WU
SUP-T1 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELsd21KSzVyPU[4Ok4xPCCwTR?= NYfXbItZW0GQR1XS
DMS-153 NFnkZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HWTWlEPTB;N{S2Mlg{KG6P M320fnNCVkeHUh?=
MS-1 NImwN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXWcFZKSzVyPUe1PU41OiCwTR?= MYrTRW5ITVJ?
TC-YIK NYnucWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTGOZVKSzVyPUe4NU4xOSCwTR?= NXfjR|ZoW0GQR1XS
RPMI-8866 M2jy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmzSIVKSzVyPUGwNFYvOjhizszN Mk[zV2FPT0WU
KY821 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHpTWM2OD1zMEO2MlA1KM7:TR?= M4HHdnNCVkeHUh?=
P31-FUJ Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzWTWM2OD1zMUGyMlc2KM7:TR?= NVLIfphOW0GQR1XS
COLO-824 M2m5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojkTWM2OD1zMk[xMlc5KM7:TR?= M37DTHNCVkeHUh?=
U-698-M M3vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnLPZB3UUN3ME2yNlYzNjF3IN88US=> MnLOV2FPT0WU
TE-441-T NF7JdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ3MkGuO{DPxE1? MWfTRW5ITVJ?
IMR-5 M4jVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN2MEmuOlIh|ryP NY\kRoJjW0GQR1XS
NCI-H1838 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL2TWM2OD12MUi2MlMzKM7:TR?= NUPZXGpSW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-PERK / ATF-4; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

GRP-78 / GADD-34; 

PubMed: 15509775     


UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-12 / pro-caspase-3; 

PubMed: 15509775     


MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. 

pro-caspase-9; 

PubMed: 15509775     


UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin.

p-IκBα / IκBα; 

PubMed: 20335171     


PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. 

COX-2 / cIAP2; 

PubMed: 24085292     


NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times.  Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin. 

15509775 20335171 24085292
Immunofluorescence
Vimentin; 

PubMed: 19010849     


ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

Ubiquitin; 

PubMed: 19010849     


IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). 

19010849
Growth inhibition assay
Cell viability ; 

PubMed: 20571067     


A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (**P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). **P < 0.01.

20571067
ELISA
IL-8; 

PubMed: 24085292     


NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.

24085292
In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03993262 Not yet recruiting Drug: Bortezomib|Drug: Placebo Autoimmune Encephalitis Jena University Hospital October 1 2019 Phase 2
NCT00425503 Completed Drug: PS-341 (bortezomib) Prostate Neoplasms Baylor College of Medicine|Millennium Pharmaceuticals Inc. December 2001 Phase 2
NCT00025376 Completed Drug: PS-341|Procedure: Tumor Biopsy Kidney Cancer University of Chicago|National Cancer Institute (NCI) October 2001 Phase 2
NCT00237627 Completed Drug: PS-341|Drug: Doxil|Drug: Velcade Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor Protocol Specific UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) May 2001 Phase 1|Phase 2
NCT00006773 Terminated Drug: bortezomib Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor National Cancer Institute (NCI) May 2001 Phase 1
NCT00373906 Completed Drug: Bortezomib (Velcade) MALT Lymphoma Medical University of Vienna Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID